Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
634 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00092482 | Immunogenicity Bridge Between an Investigational Monovalent Vaccine and the Equivalent Component of Gardasil (V501) a Quadrivalent Vaccine (V501-012)(COMPLETED) | completed | Phase 3 | 3,882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 | clinicaltrials |
| NCT00517309 | Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)(FUTURE) | completed | Phase 3 | 1,877 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 22, 2017 |
| clinicaltrials |
| NCT00322361 | Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056) | completed | Phase 2 | 566 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 16, 2017 | clinicaltrials |
| NCT00044486 | Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899) | completed | Phase 3 | 602 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 10, 2017 | clinicaltrials |
| NCT00398840 | A Study of ARQ 171 in Patients With Advanced Solid Tumors | terminated | Phase 1 | 14 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Mar 6, 2017 | clinicaltrials |
| NCT01580228 | A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) | completed | Phase 3 | 44 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 23, 2017 | clinicaltrials |
| NCT00359671 | Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001) | terminated | Phase 1 | 38 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 29, 2016 | clinicaltrials |
| NCT00337428 | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED) | completed | Phase 3 | 843 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 16, 2016 | clinicaltrials |
| NCT00705198 | Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062) | completed | — | 1,804 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 15, 2016 | clinicaltrials |
| NCT01254318 | Assessment of the Fungal Infection Incidence Across Canada for High Risk Participants With Hematological Disease (P07501)(TRAFIC) | completed | — | 130 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2016 | clinicaltrials |
| NCT00691899 | A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT00692458 | A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029) | withdrawn | Phase 3 | 0 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 12, 2016 | clinicaltrials |
| NCT01431547 | Study of Dalotuzumab Alone and With Ridaforolimus in Pediatric Participants With Advanced Solid Tumors (MK-8669-062 AM1) | completed | Phase 1 | 21 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 17, 2016 | clinicaltrials |
| NCT00729742 | Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008) | completed | Phase 1 | 49 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 4, 2016 | clinicaltrials |
| NCT00002960 | SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) | completed | Phase 1 | 59 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT00157950 | Human Papillomavirus (HPV) Registration Study (Gardasil)(V501-023)(COMPLETED) | completed | Phase 3 | 176 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT00423449 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | completed | Phase 1 | 61 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2016 | clinicaltrials |
| NCT00851643 | Broad Spectrum HPV Vaccine Dose Escalation Study (V502-002) | completed | Phase 1 | 158 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 3, 2016 | clinicaltrials |
| NCT00520598 | Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001) | completed | Phase 2 | 511 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 26, 2015 | clinicaltrials |
| NCT00110188 | Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017) | completed | Phase 2 | 39 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 20, 2015 | clinicaltrials |
| NCT00800865 | A Study to Evaluate Biomarkers in Patients With Solid Tumors (0000-097)(COMPLETED) | completed | Phase 1 | 36 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 3, 2015 | clinicaltrials |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215) | terminated | Phase 1 | 12 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 2, 2015 | clinicaltrials |
| NCT00749684 | Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083) | completed | — | 138 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 19, 2015 | clinicaltrials |
| NCT01138813 | Development of Magnetic Resonance Spectroscopy (MRS) Biomarkers of Tumor Metabolism (MK-0000-145)(MRS Tumor) | completed | — | 8 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 12, 2015 | clinicaltrials |
| NCT00635830 | An Open-Label, Single Dose Safety Study of Quadrivalent HPV Vaccine in Chinese Female Subjects (V501-035) | completed | Phase 1 | 40 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 9, 2015 | clinicaltrials |
| NCT00365716 | Dose-Ranging Study of Quadrivalent Human Papillomavirus (HPV) (Types 6,11,16,18) L1 Virus-Like Particle (VLP) Vaccine (V501-007)(COMPLETED) | completed | Phase 2 | 1,158 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 7, 2015 | clinicaltrials |
| NCT00779129 | A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948) | completed | Phase 2 | 70 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 30, 2015 | clinicaltrials |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 30, 2015 | clinicaltrials |
| NCT00127140 | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | completed | Phase 1 | 10 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 28, 2015 | clinicaltrials |
| NCT00092521 | Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) | completed | Phase 3 | 5,759 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 25, 2015 | clinicaltrials |
| NCT00479232 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | completed | Phase 1 | 71 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 21, 2015 | clinicaltrials |
| NCT00704808 | Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739) | completed | — | 180 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 9, 2015 | clinicaltrials |
| NCT00725010 | Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816) | completed | — | 64 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 9, 2015 | clinicaltrials |
| NCT01071018 | A Study of MK2206 in Locally Advanced or Metastatic Solid Tumors (2206-007) | completed | Phase 1 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 7, 2015 | clinicaltrials |
| NCT00210080 | A Study to Diagnose Lung Cancer by Sputum Cytology (01-312) | completed | Phase 3 | 700 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 4, 2015 | clinicaltrials |
| NCT00050336 | Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) | terminated | Phase 3 | 702 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT00373490 | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) | completed | Phase 1 | 16 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00736970 | Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) | completed | Phase 2 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00746694 | A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020) | completed | — | 154 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT01295632 | Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049) | completed | Phase 1 | 65 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00723710 | Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600) | completed | — | 299 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 26, 2015 | clinicaltrials |
| NCT02532868 | A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002) | terminated | Phase 1 | 27 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 26, 2015 | clinicaltrials |
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | completed | Phase 1 | 28 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 25, 2015 | clinicaltrials |
| NCT00086125 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) | completed | Phase 2 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00087451 | Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED) | completed | Phase 1 | 11 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 19, 2015 | clinicaltrials |
| NCT00418366 | A Study on the Effect of Kidney Disease on a Diabetes Medication (0431-008) | completed | Phase 1 | 24 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2015 | clinicaltrials |
| NCT00777959 | Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) | completed | Phase 2 | 22 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 19, 2015 | clinicaltrials |
| NCT01355003 | GARDASIL™ Post Marketing Surveillance in the Philippines (V501-077) | terminated | — | 1,080 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 13, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials